abm helps researchers move from concept to validated, characterization-ready organoid models with feasibility-first support and project-specific workflow development.
Building a physiologically relevant organoid model can be technically demanding. Our custom organoid generation service supports feasibility assessment, workflow design, culture optimization, and optional downstream characterization.
From iPSC- and ESC-derived models to tissue-derived (TDO) and patient-derived tumor organoids (PDO), abm supports the full range of organoid development — each project scoped to your starting material, biology, and downstream assay requirements.
Organoid development depends on the right cell source, culture conditions, and downstream assay goals. This workflow keeps each project grounded in feasibility, optimization, and clear deliverables.
Share your research goals so we can assess source material suitability, culture complexity, logistics, and project scope before moving forward.
We co-develop a project-specific plan covering matrix conditions, media formulation, growth factors, culture format, milestones, and deliverables.
Organoids are established, expanded, and iteratively optimized with morphology monitoring and documentation throughout development.
Validated models are delivered with optional downstream characterization and a feasibility review to support your next assay.
abm evaluates each project individually and supports organoid development across a wide range of tissue origins and disease applications.
Custom models for kidney-focused development and disease research.
3D culture support for neural and brain-related research questions.
Organoid workflows for lung biology and respiratory disease applications.
Project-specific planning for cardiac model development and optimization.
Feasibility review for tumour and patient-derived organoid projects.
Support for intestinal and colorectal organoid establishment and expansion.
Submit a feasibility inquiry. We review source material, organoid type, project complexity, characterization needs, and shipping feasibility before confirming scope.
From stem cell-derived systems to tissue- and patient-derived models, each project is scoped around your source material, species, and delivery requirements.
| Service category | Description | Species | Delivery format |
|---|---|---|---|
| iPSC / ESC-derived organoids | Stem cell-derived organoids generated from validated iPSC, ESC, or other pluripotent stem cell lines. |
Human Only
|
Live Only
|
| Tissue-derived organoids (TDO) | Organoids generated from fresh normal tissue, biopsy, or isolated adult stem/progenitor cells. |
MouseHuman
|
Frozen
|
| Patient-derived organoids (PDO) | Organoids generated from patient tumor tissue, biopsy, surgical specimen, malignant ascites, pleural effusion, or existing PDO culture. |
MouseHuman
|
Frozen
|
Shipping note: For iPSC/ESC-derived organoids, shipment is live only in transport medium. All PDO-related orders are shipped frozen.
Optional testing services can be added to support model validation, assay planning, and application-specific study goals.
Evaluate the response of organoids to compounds, biologics, or environmental agents to assess potential cytotoxic effects and overall tissue health.
Confirm organoid identity and differentiation status using validated molecular and cellular markers relevant to the target tissue type.
Assess the biological activity and physiological performance of organoids through tissue-specific functional assays.
Representative organoid images showing model morphology, culture progress, and optional downstream characterization outputs across different tissue and disease contexts.
Representative brightfield image showing heart organoid morphology in 3D culture.
Representative immunofluorescent image demonstrating kidney organoid characterization.
Representative brightfield image showing midbrain organoid morphology in 3D culture.
Representative brightfield image showing intestinal organoid morphology in 3D culture.
Representative brightfield image showing triple negative breast cancer organoid morphology.
Representative brightfield image of patient derived tumor organoid in 3D culture.
Each engagement is designed to reduce technical uncertainty and keep your model development aligned with downstream research needs.
Review of starting material or cell source suitability before committing scope.
Project-specific reporting and workflow development around culture requirements.
Condition, matrix, and media optimization to support model establishment.
Organoid culture initiation, establishment, expansion, and monitoring.
Progress documentation to track culture behaviour and development.
Assessment for downstream applications and next-step assay planning.
Access to abm’s broader cell biology, reagent, and assay support ecosystem.
Most organoid services are designed for high-throughput screening. abm supports researchers who need a model that may not exist yet.
Dedicated expert support from inquiry through delivery, with direct communication throughout the project.
Projects are evaluated based on your starting material, whether that's a commercial cell line, primary tissue, iPSC-derived cells, or patient-derived samples.
abm develops and manufactures supporting media, supplements, and culture formats for a more connected workflow.
Optional qPCR, IHC, and immunofluorescence outputs are available to validate your model and bridge development with downstream experimental use.
Optional downstream characterization helps bridge model development with experimental use.
Depth across renal, neural, pulmonary, cardiac, tumour, and intestinal model types — with protocol experience to support novel and established systems alike.
Common questions about custom organoid generation, starting materials, timelines, downstream applications, and project support.
abm supports custom organoid development across renal, neural, pulmonary, cardiac, intestinal, and tumour/patient-derived model types. Each project is evaluated individually, so if your tissue type isn't listed, submit a feasibility inquiry and we'll assess suitability before confirming scope.
We work with a range of source materials including commercial cell lines, primary tissue samples, iPSC-derived cells, and patient-derived samples. Suitability is reviewed during the feasibility stage before any project commitment is made.
Timelines vary based on organoid type, source material complexity, and downstream characterization requirements. After your inquiry is submitted, our team will provide a project-specific timeline as part of the feasibility and workflow design phase.
Yes. Organoid models developed through abm's service are suitable for drug screening, toxicity testing, and compound efficacy studies. Each model is optimized and characterized to ensure it meets the quality and reproducibility standards required for downstream assay use.
No prior organoid experience is required. abm's feasibility-first approach is designed to support researchers at any stage — whether you're establishing your first 3D model or optimizing an existing system. Our team works with you from inquiry through delivery to ensure the project is set up for success.
Tell us about your research goals and we’ll assess feasibility together. There is no commitment required to inquire.
Tell us about your research goals, starting material, desired model type, and downstream assay needs. Our team will review feasibility and available support options.
